<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842071</url>
  </required_header>
  <id_info>
    <org_study_id>CIMS-2008-01</org_study_id>
    <nct_id>NCT04842071</nct_id>
  </id_info>
  <brief_title>18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment</brief_title>
  <official_title>Open-label Clinical Trial on the Safety and Efficacy of 18F-sodium Fluoride (NaF) PET Imaging in Patients in Need of a Standard 99mTc Bone Scintigraphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as&#xD;
      a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of&#xD;
      universal tracer availability and higher costs contributed to the failure of 18F-NaF to&#xD;
      systematically supplant bone scintigraphy as a standard of care.&#xD;
&#xD;
      Recently, an isotope shortage crisis occurred and evidenced the need to have&#xD;
      non-reactor-derived alternatives for many nuclear medicine procedures, including bone&#xD;
      scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to&#xD;
      bone scintigraphy in case of another worldwide isotope shortage.&#xD;
&#xD;
      The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient&#xD;
      registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance&#xD;
      on diverse bone and articular diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Every patient in need and/or eligible for a standard 99mTc-biphosphonate bone scintigraphy is eligible to participate to this study. Patient data and examination results will be compiled and monitored. The safety profile of 18F-NaF produced in the primary site will be determined.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of 18F-NaF</measure>
    <time_frame>17 years</time_frame>
    <description>A registry monitoring eventual adverse effects for this radiopharmaceutical agent will be compiled. Usual procedures will be applied to divulgate any serious adverse effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy profile of 18F-NaF compared to 99mTc-biphosphonate bone scintigraphy</measure>
    <time_frame>17 years</time_frame>
    <description>Using the patient registry, and in the eventual sub-studies to come, the diagnostic performance of 18F-NaF-PET will be compared to similar available imaging tests, most notably 99mTc-biphosphonate bone scintigraphy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate 18F-NaF PET images with pathology reports</measure>
    <time_frame>17 years</time_frame>
    <description>Pathology data from the diverse conditions eligible for the 18F-NaF PET scan will be also monitored when available. Prognostic value from the imaging data will be compared with those obtained from the pathology.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Bone Cancer</condition>
  <condition>Articular Disease</condition>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>18F-NaF eligible patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-sodium fluoride</intervention_name>
    <description>Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.</description>
    <arm_group_label>18F-NaF eligible patients</arm_group_label>
    <other_name>18F-NaF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;&#xD;
&#xD;
          -  Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated for&#xD;
             oncologic or infectious reasons&#xD;
&#xD;
          -  Able to tolerate supine position&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable of maintaining supine position for more than 15 minutes&#xD;
&#xD;
          -  Refusal to sign the consent form&#xD;
&#xD;
          -  Known allergy or hypersensitivity to 18F-NaF or any of its constituants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Éric E Turcotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke, Centre de Recherche du CHUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Dubreuil</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>16617</phone_ext>
    <email>stephanie.dubreuil2@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Dubreuil</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>16617</phone_ext>
      <email>Stephanie.Dubreuil2@Usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Éric Turcotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université deSherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric E Turcotte, MD</last_name>
      <phone>346-1110</phone>
      <phone_ext>11887</phone_ext>
      <email>eric.e.turcotte@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Dubreuil</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>16617</phone_ext>
      <email>Stephanie.dubreuil2@usherbrooke.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Dr Éric E Turcotte, MD</investigator_full_name>
    <investigator_title>Head of clinical research, CIMS, CRCHUS</investigator_title>
  </responsible_party>
  <keyword>18F-NaF</keyword>
  <keyword>Bone scintigraphy</keyword>
  <keyword>bone diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

